TRU Simulation Announces Acceptance of First Unit Training Device Delivery for the Multi-Engine Training System Ground Based Training System Contract; Contract Options Exercised for Additional Devices and Support
26.3.2025 17:00:00 CET | Business Wire | Press release
TRU Simulation + Training Inc. today announced the acceptance of the first of three Unit Training Device (UTD) simulators as part of the Multi-Engine Training System (METS) Ground Based Training System (GBTS) contract by Naval Air Warfare Center – Training Systems Division (NAWCTSD). In addition, a recent contract modification exercised added options outlined in the contract base award, including upgrading two UTDs, the delivery of four additional OFTs and extension of various support services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326459131/en/
TRU Simulation announced the acceptance of the first of three Unit Training Device (UTD) simulators as part of the Multi-Engine Training System (METS) Ground Based Training System (GBTS) contract by Naval Air Warfare Center – Training Systems Division (NAWCTSD). (Photo credit: TRU Simulation)
TRU Simulation, an affiliate of Textron Aviation Inc., is a Textron Inc. (NYSE: TXT) company that designs, manufactures and delivers high-fidelity training devices and full-motion simulators for civil and defense customers.
"At TRU, we are proud to support the METS GBTS mission of providing an intermediate and advanced training platform for U.S. Navy, U.S. Marine Corps and U.S. Coast Guard aviators. Our on-time delivery of the first UTD reinforces TRU’s commitment to delivering innovative and reliable solutions to meet our customers’ evolving needs," said Jerry Messaris, vice president and general manager, TRU Simulation. "TRU Simulation is eager to continue our history of building high-fidelity devices to support critical missions."
In November 2024, TRU received a Letter of Equivalency qualifying the UTD as an authorized Level 7 Flight Simulation Training Device (FSTD) from the Federal Aviation Administration (FAA). Additionally, TRU successfully achieved on-time delivery and acceptance of 21 Desktop Avionics Trainers (DATs) for the METS program.
The contract base award was for three Unit Training Device (UTD) simulators in a King Air 260 standard commercial configuration for fixed wing flight training, one Operational Flight Trainer (OFT) simulator in the METS T-54A configuration for higher fidelity and dynamic flight training operations, one Simulator Support Station (SSS) in the METS T-54A configuration to support the software maintenance of the deployed devices and 21 Desktop Trainers for classroom avionics training. TRU will provide device instructor and maintenance training, spares, as well as Contractor Logistics Services (CLS), to support the fielded devices in Corpus Christi, Texas. The contract was awarded through a full and open competition, and deliveries are expected to continue through 2026.
About TRU Simulation
TRU Simulation + Training Inc., an affiliate of Textron Aviation Inc., is a leading provider of high-fidelity training devices and full-motion simulators for the aviation industry. With a strong commitment to excellence and innovation, TRU Simulation has been at the forefront of flight simulation technology for over a decade. Our customized simulator solutions empower pilots to navigate the skies confidently, while our state-of-the-art technology ensures safe and realistic training experiences. For more information, visit www.TRUSimulation.com.
About Textron Aviation
We inspire the journey of flight. For more than 95 years, Textron Aviation Inc., a Textron Inc. company, has empowered our collective talent across the Beechcraft, Cessna and Hawker brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops, and high-performance pistons, to special mission, military trainer and defense products, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable and flexible flight.
For more information, visit www.txtav.com|www.defense.txtav.com|www.scorpionjet.com.
About Textron Inc.
Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, Arctic Cat, Textron Systems, and TRU Simulation. For more information, visit: www.textron.com.
Certain statements in this press release are forward-looking statements which may project revenues or describe strategies, goals, outlook or other non-historical matters; these statements speak only as of the date on which they are made, and we undertake no obligation to update or revise any forward-looking statements. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326459131/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom